Targets › PKP2
3 programs from 3 companies in 3 trials: 3 Phase 1; Cardiovascular; next expected readout Dec 2026.
A component of desmosome cell-cell junctions which are required for positive regulation of cellular adhesion. Regulates focal adhesion turnover resulting in changes in focal adhesion size, cell adhesion and cell spreading, potentially via transcriptional modulation of beta-integrins. (UniProt, Q99959)
Open in Phaseline: the race on PKP2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Lexeo Therapeutics | LX2020 Adeno-associated viral vector (AAVrh.10) encoding human Plakophilin-2 (PKP2) gene | PKP2 | Phase 1 | Arrhythmogenic Cardiomyopathy | Dec 2026 |
| Rocket Pharmaceuticals | RP-A601 AAV serotype rh.74 vector encoding human plakophilin 2 (PKP2) | PKP2 | Phase 1 | PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) | Sep 2028 |
| Tenaya Therapeutics | TN-401 AAV9 gene therapy delivering PKP2 transgene | PKP2 | Phase 1 | Arrhythmogenic Right Ventricular Cardiomyopathy | Oct 2029 |
Arrhythmogenic Right Ventricular Cardiomyopathy (1) PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) (1) Arrhythmogenic Cardiomyopathy (1)
other (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.